Sanofi
SAN
Hisse Senetlerindeki Sıralama
#224
Sanofi is a global healthcare enterprise dedicated to the research,... Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
Hisse Fiyatı
$83.84
Piyasa Değeri
$100.45B
Değişim (1 gün)
1.48%
Değişim (1 yıl)
-16.74%
Ülke
FR
Ticaret Sanofi (SAN)
Kategori
Healthcare
Sanofi (SAN) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: 20.58%
Sanofi şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 20.58%'dir. 2024 yılı sonunda şirketin faaliyet marjı 32.63% idi.
Sanofi için 2001 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | 20.58% | 0.19% |
| 2025 | 20.54% | -37.05% |
| 2024 | 32.63% | 3.36% |
| 2023 | 31.57% | -3.22% |
| 2022 | 32.62% | 57.28% |
| 2021 | 20.74% | -45.09% |
| 2020 | 37.77% | 365.72% |
| 2019 | 8.11% | -38.14% |
| 2018 | 13.11% | -18.16% |
| 2017 | 16.02% | -14.88% |
| 2016 | 18.82% | 16.68% |
| 2015 | 16.13% | -14.88% |
| 2014 | 18.95% | 19.03% |
| 2013 | 15.92% | -28.19% |
| 2012 | 22.17% | 35.60% |
| 2011 | 16.35% | -12.14% |
| 2010 | 18.61% | -10.10% |
| 2009 | 20.70% | -38.90% |
| 2008 | 33.88% | 67.39% |
| 2007 | 20.24% | 4.17% |
| 2006 | 19.43% | -25.64% |
| 2005 | 26.13% | -1,593.14% |
| 2004 | -1.75% | -104.58% |
| 2003 | 38.21% | 8.89% |
| 2002 | 35.09% | 8.10% |
| 2001 | 32.46% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 49.72% | -97.58% |
US
|
|
| 25.70% | -98.75% |
US
|
|
| 29.32% | -98.58% |
US
|
|
| 16.65% | -99.19% |
US
|
|
| 31.92% | -98.45% |
CH
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.